Good MorningThe equities markets continue to prove their resilience by holding post-pandemic highs into the close of last week’s trading. The S&P 500 closed on Friday with barely a budge from the previous day’s session and up nearly 3.5% for the week. While not a robust move, the action is bullish and proves the smart money unwilling to be out of the market ahead of next week’s earnings deluge.
Next week begins the peak of earnings season. There are 92 S&P 500 companies set to report including 8 Dow Components. To date, roughly three-quarters of companies that already reported for the quarter beat their estimates. Although the 2nd quarter cycle won’t be good regarding earnings growth it is shaping up to be much better than expected. The risk for traders now is the virus and how it may impact the second half of the year. If the outlook for earnings does not continue to improve the equity market could be in for another deep plunge.
Featured: System Used by Top 1% Investors to Pick Winning Stocks (True Market Insiders) 
|
Markets | | |
These days, people tend to treat their pets as true members of the family. If you are a pet owner, you understand the need for certain animal medicine products that keep your furry friends happy and healthy. While treatments like heartworm protection and flea medication might not appear as lucrati... Read the Full Story |
|
From Our PartnersIf it seems like the crisis in America is only getting started, you're right. While most people are focusing on face masks and stimulus checks... they're ignoring what's really happening... the NEXT big and inevitable event, which will determine your financial future, and how much you have for retirement. | | To learn the facts - not reported like this anywhere else - click here. |
|
Markets | | | It All Begins With Trucking
Old-school Dow Theorists will tell you that everything economic begins and ends with trucking. If the economy is gearing up for expansion you’ll it first in the trucking data. If the economy is preparing for a slowdown you will see that in the data as well. What we... Read the Full Story |
|
Markets | | |
There was little doubt that Netflix (NASDAQ: NFLX) was going to walk out of the second quarter on top of the world. It had exactly what people needed in the second quarter, and was ready to deliver it up to as many comers as were interested. The question was, could it possibly carry on that way in... Read the Full Story |
|
Markets | | |
The coronavirus pandemic has had a profound impact on the restaurant industry and The Cheesecake Factory (NASDAQ: CAKE) has been no exception.
Closed dining rooms, furloughed workers, and dramatically lower sales were certainly not what the chef ordered for 2020. The uncertain environment caused ... Read the Full Story |
|
Markets | | |
Autoliv Misses On The Top And Bottom Line
Autoliv (NYSE:ALV) is a manufacturer of automotive safety equipment specifically for the OEM market. It’s products range from airbags to seatbelts and steering wheels to child safety seats so it is no wonder the company saw a major downturn in busin... Read the Full Story |
|
|
The Early Bird Stock Of The Day Magenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. | | View Today's Stock Pick |
|
